Chrysalis 2 Study
About NSCLC &
Biomarkers
About NSCLC
About Biomarkers
Understanding Biomarkers Why Get Tested FAQs
About Clinical
Research Studies
Understanding Clinical Research Why Participate FAQs
Current Clinical
Research Studies
Current Studies
Chrysalis Study Chrysalis 2 Study Mariposa 2 Study Papillon Study
Study Locations
Participating Countries
For Healthcare
Providers
For Caregivers &
Loved Ones
Additional
Resources
NSCLC Support Janssen Oncology Research
EN-US
ES-US EN-AU
See If You Are Eligible
1-855-218-4395

About The Chrysalis 2 Study

The CHRYSALIS 2 Study is evaluating the safety and effectiveness of an investigational medication in combination with another investigational medication for different groups of people with advanced NSCLC.
The study includes multiple groups of people with NSCLC who have a range of different characteristics and types of cancer/subtypes. These study groups may not all be recruiting new participants at the same time.

See If You Are Eligible

You may be able to take part in the CHRYSALIS 2 Study if you:

  • Are 18 years or older
  • Have been diagnosed with advanced NSCLC and also have one of the following gene mutations: Uncommon non-Exon 20 insertion activating mutations including but not limited to S768I, L861Q, and G719X - Other uncommon EGFR mutations may be considered
Additional eligibility criteria will be assessed by the study doctor or staff.

See If You Are Eligible

For additional information:

Download the CHRYSALIS 2 Fact Sheet
What’s involved with study participation?

Participants will receive the investigational medication or combination of investigational medications while completing various study tests and procedures.

  • The study duration will vary from person to person depending on the response to investigational medication(s).
  • Each investigational medication cycle will last 28 days. Participants and the study staff will know which investigational medication or medications are being given. There is no placebo in this study.
  • Investigational medications will be administered orally (daily) and intravenously (in a vein) once a week during the first investigational medication cycle, then every 2 weeks after.
  • Participants may leave the study at any point in time.
Does participating in this study cost me anything?

All study-required visits, tests, and medications will be provided at no cost to qualified participants. The study will not pay for other medical care or current medication(s) needed to support your daily healthcare routine. In addition, reimbursement for study-required travel, meals, and parking may be available.

If pre-qualified, what can I expect on my first visit to the study clinic?

This initial appointment is an opportunity for you to:

  • Learn more about the CHRYSALIS 2 Study. You’ll be speaking with a study doctor at the study clinic to learn more regarding your participation in this study.
  • Ask any important questions you may have. These can be any questions you may have about this study or clinical research in general.
  • Determine if the CHRYSALIS 2 Study may be right for you. After speaking with the study doctor and learning details about this study, the study staff will perform a series of screening tests to determine if you are eligible to participate. If you are eligible, you and your doctor can then decide if this study is right for you. No tests for the actual study will be given at this time. If you agree to take part, the study staff will ask you to review and sign a consent form.
What can I expect if I join the study?

Participants in CHRYSALIS 2 study will be assigned to different cohorts based on their mutational status. All participants in all cohorts will receive the same two investigational medications in combination and at the same dose. This is an open-label study, which means that you will know which investigational medications you are receiving. There is no placebo in this study.

  • The oral investigational medication will be taken orally once a day.
  • The other investigational medication will be administered through intravenous infusion every week for the first 4 weeks, then once every 2 weeks.
What if my condition worsens or I have side effects?

You should make sure to inform your doctor of any new symptoms you experience while participating in the study. If you experience worsening of your disease at any time during the study, your study doctor will ask you to come to the study clinic to determine disease progression. If your disease is progressing, you will be asked to complete an end of study treatment visit 30 days after your last dose of investigational medication. You will then enter the follow-up phase with visits to the study clinic or telephone contact every 12 weeks until the end of study to find out how you are doing, if you have had any side effects, and if you have started any new cancer treatments.

Where are the study clinics located?

There are study clinics located throughout the United States. Find a location near you.

To see a list of participating study clinics in over 20 countries globally, visit this page.

For additional information:

Download the CHRYSALIS 2 Fact Sheet
Consider enrolling in this study today.
See If You Are Eligible
If you have EGFR-Positive Non-Small-Cell Lung Cancer, your journey may include a different path.

The more we learn, the farther we can go.

See If You Are Eligible